132 related articles for article (PubMed ID: 27708243)
1. JWA down-regulates HER2 expression via c-Cbl and induces lapatinib resistance in human gastric cancer cells.
Ma L; Zhu W; Wang Q; Yang F; Qian J; Xu T; Wang S; Zhou J; Shu Y
Oncotarget; 2016 Nov; 7(44):71790-71801. PubMed ID: 27708243
[TBL] [Abstract][Full Text] [Related]
2. Functional genetic approach identifies MET, HER3, IGF1R, INSR pathways as determinants of lapatinib unresponsiveness in HER2-positive gastric cancer.
Zhang Z; Wang J; Ji D; Wang C; Liu R; Wu Z; Liu L; Zhu D; Chang J; Geng R; Xiong L; Fang Q; Li J
Clin Cancer Res; 2014 Sep; 20(17):4559-73. PubMed ID: 24973425
[TBL] [Abstract][Full Text] [Related]
3. JWA loss promotes cell migration and cytoskeletal rearrangement by affecting HER2 expression and identifies a high-risk subgroup of HER2-positive gastric carcinoma patients.
Qian J; Zhu W; Wang K; Ma L; Xu J; Xu T; Røe OD; Li A; Zhou J; Shu Y
Oncotarget; 2016 Jun; 7(24):36865-36884. PubMed ID: 27167206
[TBL] [Abstract][Full Text] [Related]
4. FOXO1 Suppression is a Determinant of Acquired Lapatinib-Resistance in HER2-Positive Gastric Cancer Cells Through MET Upregulation.
Park J; Choi Y; Ko YS; Kim Y; Pyo JS; Jang BG; Kim MA; Lee JS; Chang MS; Park JW; Lee BL
Cancer Res Treat; 2018 Jan; 50(1):239-254. PubMed ID: 28343375
[TBL] [Abstract][Full Text] [Related]
5. Testican-1-mediated epithelial-mesenchymal transition signaling confers acquired resistance to lapatinib in HER2-positive gastric cancer.
Kim HP; Han SW; Song SH; Jeong EG; Lee MY; Hwang D; Im SA; Bang YJ; Kim TY
Oncogene; 2014 Jun; 33(25):3334-41. PubMed ID: 23873022
[TBL] [Abstract][Full Text] [Related]
6. A novel treatment strategy for lapatinib resistance in a subset of HER2-amplified gastric cancer.
Ning G; Zhu Q; Kang W; Lee H; Maher L; Suh YS; Michaud M; Silva M; Kwon JY; Zhang C; Lee C
BMC Cancer; 2021 Aug; 21(1):923. PubMed ID: 34399705
[TBL] [Abstract][Full Text] [Related]
7. JWA reverses cisplatin resistance via the CK2-XRCC1 pathway in human gastric cancer cells.
Xu W; Chen Q; Wang Q; Sun Y; Wang S; Li A; Xu S; Røe OD; Wang M; Zhang R; Yang L; Zhou J
Cell Death Dis; 2014 Dec; 5(12):e1551. PubMed ID: 25476899
[TBL] [Abstract][Full Text] [Related]
8. Chk1 activation attenuates sensitivity of lapatinib in HER2-positive gastric cancer.
Bai M; Song N; Che X; Wang X; Qu X; Liu Y
Cell Biol Int; 2018 Jul; 42(7):781-793. PubMed ID: 29271513
[TBL] [Abstract][Full Text] [Related]
9. Combined effects of lapatinib and bortezomib in human epidermal receptor 2 (HER2)-overexpressing breast cancer cells and activity of bortezomib against lapatinib-resistant breast cancer cells.
Ma C; Niu X; Luo J; Shao Z; Shen K
Cancer Sci; 2010 Oct; 101(10):2220-6. PubMed ID: 20701607
[TBL] [Abstract][Full Text] [Related]
10. Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1.
Nonagase Y; Yonesaka K; Kawakami H; Watanabe S; Haratani K; Takahama T; Takegawa N; Ueda H; Tanizaki J; Hayashi H; Yoshida T; Takeda M; Chiba Y; Tamura T; Nakagawa K; Tsurutani J
Oncotarget; 2016 Dec; 7(51):84860-84871. PubMed ID: 27768588
[TBL] [Abstract][Full Text] [Related]
11. PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim.
Park SH; Ito K; Olcott W; Katsyv I; Halstead-Nussloch G; Irie HY
Breast Cancer Res; 2015 Jun; 17(1):86. PubMed ID: 26084280
[TBL] [Abstract][Full Text] [Related]
12. miR‑494 inhibits cancer‑initiating cell phenotypes and reverses resistance to lapatinib by downregulating FGFR2 in HER2‑positive gastric cancer.
Yu Y; Yu X; Liu H; Song Q; Yang Y
Int J Mol Med; 2018 Aug; 42(2):998-1007. PubMed ID: 29786108
[TBL] [Abstract][Full Text] [Related]
13. Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer.
Takeda T; Yamamoto H; Kanzaki H; Suzawa K; Yoshioka T; Tomida S; Cui X; Murali R; Namba K; Sato H; Torigoe H; Watanabe M; Shien K; Soh J; Asano H; Tsukuda K; Kitamura Y; Miyoshi S; Sendo T; Toyooka S
PLoS One; 2017; 12(2):e0171356. PubMed ID: 28158234
[TBL] [Abstract][Full Text] [Related]
14. Molecular effects of Lapatinib in the treatment of HER2 overexpressing oesophago-gastric adenocarcinoma.
De Silva N; Schulz L; Paterson A; Qain W; Secrier M; Godfrey E; Cheow H; O'Donovan M; Lao-Sirieix P; Jobanputra M; Hochhauser D; Fitzgerald R; Ford H
Br J Cancer; 2015 Nov; 113(9):1305-12. PubMed ID: 26484410
[TBL] [Abstract][Full Text] [Related]
15. Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: a randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.
Lorenzen S; Riera Knorrenschild J; Haag GM; Pohl M; Thuss-Patience P; Bassermann F; Helbig U; Weißinger F; Schnoy E; Becker K; Stocker G; Rüschoff J; Eisenmenger A; Karapanagiotou-Schenkel I; Lordick F
Eur J Cancer; 2015 Mar; 51(5):569-76. PubMed ID: 25694417
[TBL] [Abstract][Full Text] [Related]
16. RNF185 modulates JWA ubiquitination and promotes gastric cancer metastasis.
Qiu D; Wang Q; Wang Z; Chen J; Yan D; Zhou Y; Li A; Zhang R; Wang S; Zhou J
Biochim Biophys Acta Mol Basis Dis; 2018 May; 1864(5 Pt A):1552-1561. PubMed ID: 29481911
[TBL] [Abstract][Full Text] [Related]
17. JWA suppresses tumor angiogenesis via Sp1-activated matrix metalloproteinase-2 and its prognostic significance in human gastric cancer.
Chen Y; Huang Y; Huang Y; Xia X; Zhang J; Zhou Y; Tan Y; He S; Qiang F; Li A; Re OD; Li G; Zhou J
Carcinogenesis; 2014 Feb; 35(2):442-51. PubMed ID: 24072772
[TBL] [Abstract][Full Text] [Related]
18. Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib.
Huang W; Wu QD; Zhang M; Kong YL; Cao PR; Zheng W; Xu JH; Ye M
Cancer Lett; 2015 Jan; 356(2 Pt B):862-71. PubMed ID: 25449780
[TBL] [Abstract][Full Text] [Related]
19. Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification.
Tanizaki J; Okamoto I; Fumita S; Okamoto W; Nishio K; Nakagawa K
Oncogene; 2011 Sep; 30(39):4097-106. PubMed ID: 21499301
[TBL] [Abstract][Full Text] [Related]
20. Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo.
Wainberg ZA; Anghel A; Desai AJ; Ayala R; Luo T; Safran B; Fejzo MS; Hecht JR; Slamon DJ; Finn RS
Clin Cancer Res; 2010 Mar; 16(5):1509-19. PubMed ID: 20179222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
